

1 **Hybrid humoral immune response of Pacific Islanders to BNT162b2 vaccination and**
2 **Delta/Omicron infection: a cohort study**

3
4 Catherine Inizan^{1,12,*}, Adrien Courtot², Chloé Sturmach^{3,4}, Anne-Fleur Griffon¹, Antoine Biron⁵,
5 Timothée Bruel^{6,7,8}, Vincent Enouf^{3,4}, Thibaut Demaneuf^{9,§}, Sandie Munier⁴, Olivier Schwartz^{7,8}, Ann-
6 Claire Gourinat^{5,#}, Georges Médevielle², Marc Jouan¹, Sylvie van der Werf^{3,4}, Yoann Madec¹⁰, Valérie
7 Albert-Dunais¹¹, Myrielle Dupont-Rouzeyrol¹.

8
9 1. Dengue and Arboviroses – Research and Expertise Unit - Institut Pasteur in New Caledonia - Pasteur
10 Network, 110 Bvd Joseph Wamytan, 98835 Dumbéa-sur-Mer, New Caledonia.

11 2. Provincial Office for Health and Social Action of the South Province (Direction Provinciale de
12 l’Action Sanitaire et Sociale en Province Sud), 12 rue de Verdun, 98800 Nouméa, New Caledonia

13 3. National Reference Center for Respiratory Viruses, Institut Pasteur, Université Paris Cité, Paris,
14 France.

15 4. Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569,
16 Paris, France

17 5. New Caledonia Territorial Hospital, 110 Bvd Joseph Wamytan, 98835 Dumbéa-sur-Mer, New
18 Caledonia

19 6. Antiviral Activities of Antibodies Group, Institut Pasteur, Université Paris Cité, CNRS UMR3569,
20 Paris, France

21 7. Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France

22 8. Vaccine Research Institute, Créteil, France

23 9. Social and Sanitary Agency of New Caledonia (Agence Sanitaire et Sociale de Nouvelle-Calédonie),
24 Nouméa, New Caledonia

25 10. Epidemiology of Emerging Diseases, Institut Pasteur, Université de Paris, 75000 Paris, France.

26 11. New Caledonia Specialized Hospital, 42 rue Eschembrenner, Nouville BP 120, 98845 Nouméa, New
27 Caledonia.

28 12. Lead contact

29 §: Current address: Pacific Community SPC – Public Health Division – B.P. D5, 98800 Nouméa, New
30 Caledonia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 31 #: Current address: New Caledonia Health Authorities (Direction des Affaires Sanitaires et Sociales de
32 Nouvelle-Calédonie), 7 ave Paul Doumer, BM M2, 98849 Nouméa Cedex, New Caledonia
33 *Correspondence: cinizan@pasteur.nc

34 **Summary**

35 **Background**

36 Pacific Islanders are underrepresented in vaccine efficacy trials. Few studies describe their immune
37 response to COVID-19 vaccination. Yet, this characterization is crucial to re-enforce vaccination
38 strategies adapted to Pacific Islanders singularities.

39 **Methods**

40 We evaluated the humoral immune response of 585 adults self-declaring as Melanesians, Europeans,
41 Polynesians or belonging to other communities to Pfizer BNT162b2 vaccine. Anti-Spike and anti-
42 Nucleoprotein IgG levels, capacity to neutralize SARS-CoV-2 variants and capacity to mediate
43 Antibody-Dependent Cellular Cytotoxicity (ADCC) were assessed across communities at one and three
44 months post-second dose or one and six months post-third dose.

45 **Results**

46 61.3% of the sera tested contained anti-Nucleoprotein antibodies, evidencing mostly a hybrid immunity
47 resulting from vaccination and SARS-CoV-2 infection. Anti-Spike IgG levels and capacity to mediate
48 Omicron neutralization and ADCC were equivalent across the four ethnic communities at one-month
49 post-immunization, during follow-up and at six months post-third dose, regardless of the infection
50 status. Obese individuals ($BMI > 30 \text{ kg/m}^2$) had significantly higher anti-Spike IgG levels at one-month
51 post-immunization (+0.26 (0.04; 0.48) AU in LuLISA assay, p value = 0.017). Odds of Omicron
52 neutralization at six months after the third dose decreased significantly in the 40-64 years and ≥ 65 years
53 groups (OR (95% CI) 0.48 (0.24-0.90) and 0.29 (0.14-0.58) respectively, p -value = 0.003).

54 **Conclusions**

55 Our study evidenced Pacific Islander's robust humoral immune response to Pfizer BNT162b2 vaccine,
56 which is pivotal to re-enforce vaccination deployment in a population at risk for severe COVID-19
57 (clinicaltrials.gov: NCT05135585).

58 **Keywords**

- 59 COVID-19 vaccines; Pfizer BNT162b2; Immunity, humoral; antibodies; Pacific Island people;
- 60 neutralization; Antibody-Dependent Cell Cytotoxicity

61 **40-words summary**

62 Ethnicity has little impact on Pacific Islanders' hybrid humoral immune response to BNT162b2
63 vaccination and SARS-CoV-2 infection. Anti-Spike IgG levels, capacity to neutralize Omicron variants
64 and capacity to mediate Antibody-Dependent Cellular Cytotoxicity are equivalent across Pacific
65 communities following BNT162b2 vaccination.

66 **Introduction**

67 Covering 8.5 million km² in a maritime area of 80 million km², emerged Pacific territories excluding
68 Australia are populated by ≈17 million inhabitants, among which 11.6 million belong to communities
69 of Non-European Non-Asian descent ¹. Pacific Islanders are at risk of severe respiratory infections,
70 including influenza ² and COVID-19 ³. As vaccination protects from severe COVID-19 in cohorts
71 mostly composed of White people ⁴, it is pivotal to assess whether Pacific Islanders' humoral response
72 to anti-COVID-19 vaccination is equivalent to the one of White people.

73 New Caledonia (NC) is a French overseas territory of ≈270,000 inhabitants in the South Pacific region,
74 where 41.2% self-declare as Melanesian, 24% as European, 8.3% as Polynesian and 26.5% as belonging
75 to other communities ⁵.

76 A zero COVID policy protected NC from early SARS-CoV-2 spread. In September 2021, the first
77 epidemic peak was caused by the Delta variant. Two larger epidemic peaks due to Omicron BA.1 and
78 BA.4/5 occurred in 2022 (Supplementary figure 1). Almost 80,000 infections and 314 deaths were
79 detected ^{6,7}. Vaccination roll-out, involving almost exclusively Pfizer BNT162b2 vaccine, was initiated
80 in January 2021. As of May 2023, 70% of the entire population had received at least one dose, 68% had
81 received at least two doses and 38% had received a booster dose ⁸.

82 Considering ethnic representation in COVID-19 vaccine trials is crucial ⁹. However, in Pfizer
83 BNT162b2 efficacy trial, the cohort included only 0.2% Native Hawaiians/other Pacific Islanders ¹⁰,
84 precluding to assess vaccine efficacy in this population. As a consequence, data on anti-SARS-CoV-2
85 immunity in vaccinated Pacific populations remain scarce. In a New Zealand cohort study, the 80 Pacific
86 people included had lower anti-SARS-COV-2 antibody titers than Europeans and Maoris 28 days after
87 two doses of BNT162b2 vaccine. However, when adjusting for the higher prevalence of diabetes in
88 Pacific people, antibody titers and variant neutralization did not differ by ethnicity ¹¹. Similarly,
89 Australian First Nations people deployed a prototypical immune response to Pfizer BNT162b2 vaccine,
90 with humoral and cellular responses at similar levels than Non-Indigenous people ¹².

91 Anti-Spike antibody levels, neutralization capacity and antibodies functionality, including Antibody-
92 Dependent Cellular Cytotoxicity (ADCC)¹³, play an important role in COVID-19 pathogenesis. ADCC
93 was indeed higher in hospitalized or severe patients who survived than in fatal cases^{13,14}, suggesting its
94 protective role.

95 Adaptation of regional vaccination strategies to Pacific populations' singularities requires to evaluate
96 COVID-19 vaccines' immunogenicity and hybrid immunity upon breakthrough infection in Pacific
97 populations. The current study postulated that the hybrid humoral response to Pfizer BNT162b2 vaccine
98 was equivalent across the four ethnic communities in NC. We aimed to characterize Pacific Islanders'
99 hybrid humoral response to BNT162b2 vaccine and SARS-CoV-2 infection, by evaluating anti-Spike
100 IgG levels, the neutralization capacity and the ability to mediate ADCC of sera longitudinally collected
101 in a cohort of 585 vaccinated adults from New Caledonia self-declaring as Melanesians, Polynesians,
102 Europeans or belonging to other communities.

103 **Results**

104 *Hybrid humoral response was highly prevalent in the cohort.*

105 This study enrolled 585 participants, among which 148 self-declared as Melanesians, 189 as Europeans,
106 82 as Polynesians and 166 as belonging to other communities. Sixty-eight participants were sampled at
107 one month post-second dose (D2.1) and 56 participants were sampled at three months post-second dose
108 (D2.3), of whom 50 participants were sampled at both timepoints (Figure 1). A total of 237 participants
109 were sampled at 1 month post-third dose (D3.1) and 488 participants were sampled at 6 months post-
110 third dose (D3.6), of whom 214 participants were sampled at both timepoints (Figure 1). Overall, 849
111 blood samples were collected and analyzed. All samples contained anti-Spike IgG.

112 Eighty-five participants (14.5%) reported a positive COVID-19 test at one of the sampling timepoints.
113 Participants exhibiting anti-Nucleocapsid antibodies, sign of a previous or current infection, at D2.1,
114 D2.3, D3.1 and D3.6, were 47 (69.1%), 43 (76.8%), 150 (63.3%) and 280 (57.4%), respectively (Figure
115 2). In the 18 and 113 participants with anti-Nucleocapsid antibodies and followed up between D2.1/D2.3
116 or D3.1/D3.6, 9 re-infections and 9 new infections despite immunization (breakthrough infections) and

117 73 re-infections and 40 breakthrough infections were identified after the second and the third dose,
118 respectively. Subsequent multivariate regression and logistic models were adjusted for infection status.

119 *Humoral response at one-month post-vaccination is equivalent across ethnic communities.*

120 Among the 305 participants sampled at one-month post-immunization (68 and 237 sampled at D2.1 and
121 D3.1, respectively), ethnicity was distributed as follows: 55 Melanesians, 79 Europeans, 55 Polynesians
122 and 116 participants belonging to other communities (Supplementary Table 1). The proportion of
123 women was 54.6%. Age of participants ranged from 19 to 82 years, with European participants
124 significantly older ($p=0.002$, Kruskal-Wallis). Previous infection was significantly less frequent in
125 Europeans ($p=0.005$, Khi-2 test). BMI was significantly lower in Europeans ($p<0.001$, Kruskal-Wallis
126 test).

127 Levels of anti-Spike IgG (anti-S IgG, $p<0.001$, Table 1 and Supplementary Table 2) and the ability to
128 neutralize Omicron ($p<0.001$, Supplementary Table 2) were significantly higher one month after the
129 third dose than after the second dose, irrespective of the infection status (Figure 3a). Previous SARS-
130 CoV-2 infection was significantly associated with higher titers after the third dose ($p<0.001$, Figure 3A).
131 After the second dose, Omicron neutralization was significantly more frequent in those with a previous
132 infection ($p=0.004$, Table 2).

133 Linear regression confirmed that number of doses and infection status were independently and
134 significantly associated with higher anti-S IgG titers (adjusted effect +1.27, 95% CI (1.06; 1.49),
135 $p<0.001$ and + 0.38, 95% CI (0.19; 0.56), $p<0.001$, respectively, Table 1). Obesity was associated with
136 significantly higher anti-S IgG titers (adjusted effect +0.24, 95% CI (+0.03; +0.46), $p=0.008$). Male
137 gender was significantly associated with lower anti-S IgG titers (adjusted effect -0.19, 95% CI (-0.37; -
138 0.01), $p=0.036$). Importantly, ethnic community was not associated with anti-S IgG titers ($p= 0.34$)
139 (Figure 3B).

140 In a ROC curve analysis, a threshold of 5.737 AU maximized the proportion of subjects exhibiting anti-S
141 IgG levels above the threshold who were able to neutralize Omicron (75% sensitivity) while minimizing

142 the proportion of participants below the threshold able to neutralize Omicron (95% specificity)
143 (Supplementary figure 2).

144 Pseudovirus neutralization assays showed that almost all individuals sampled one month after
145 immunization were able to neutralize the vaccine strain Wuhan and the Delta variant (Figure 3C). The
146 ability to neutralize Omicron BA.1 and/or BA.4/5 however significantly differed by number of doses
147 (Figure 3C), with 19.1% and 97.9% participants neutralizing Omicron after the second and third dose,
148 respectively (Supplementary Table 2). In analyses stratified by immunization dose, only anti-S IgG
149 levels were significantly associated with neutralization (OR (95% CI): 88.33 (15.79-805.92), $p < 0.001$
150 at D2.1, and 12.00 (1.73-237.30), $p = 0.028$ at D3.1 Table 2). After two immunizations, only anti-S IgG
151 levels remained significantly associated with Omicron neutralization ($p < 0.001$). After three
152 immunizations, in univariate analysis, no factor other than anti-S IgG levels ($p = 0.028$) was associated
153 with Omicron neutralization (all p -values > 0.20). Importantly, ethnic community was not associated with
154 different odds to neutralize Omicron ($p = 0.59$ and $p = 0.60$ at D2.1 and D3.1, respectively).

155 All participants but 7 were able to activate CD16 following exposure to SARS-CoV-2 Spike, reflecting
156 a capacity to mediate ADCC. Multivariate linear regression showed that anti-S IgG levels ≥ 5.737 AU
157 and male gender were independently associated with higher ADCC activation (+0.61 (0.29; 0.94),
158 $p < 0.001$ and +0.47 (0.14; 0.79), $p = 0.005$, respectively, Table 3). Importantly, ethnic community was
159 not associated with the capacity to mediate ADCC ($p = 0.069$ in multivariate linear regression).

160 *Humoral response to SARS-CoV-2 over 6 months post-third dose is similar across ethnic communities*

161 Among the 214 participants who were evaluated at both D3.1 and D3.6, 29 self-declared as Melanesians,
162 57 as Europeans, 42 as Polynesians and 86 as belonging to other communities (Supplementary table 3).
163 Europeans were significantly older ($p = 0.022$, Kruskal-Wallis test), showed less frequently signs of
164 previous infection ($p = 0.059$, χ^2 test) and had lower BMI ($p < 0.001$, Kruskal-Wallis test)
165 (Supplementary table 3). Between D3.1 and D3.6, anti-S IgG levels decreased in median (IQR) by 1.67
166 AU (0.63; 2.59) (Supplementary table 3). The multivariate linear regression model showed that in
167 participants never infected and with anti-S IgG levels < 5.737 at D3.1, the anti-S IgG levels decreased

168 (in mean (95% CI)) by 1.98 AU (1.56; 2.39) between D3.1 and D3.6 (Supplementary table 4). In
169 participants with anti-S IgG levels >5.737 at D3.1, the decrease was significantly steeper (-2.52 AU (-
170 2.90; -2.14), $p<0.001$). In participants with breakthrough infection, anti-S IgG levels remained stable.

171 Two hundred and nine participants out of 214 showed the ability to neutralize Omicron at D3.1
172 (Supplementary table 3). Of them, 35 (16.7%) had lost this ability by D3.6 (Supplementary table 3).
173 Multivariate logistic regression evidenced that previously infected individuals had significantly lower
174 odds to lose Omicron neutralization capacity (adjusted OR (95% CI): 0.20 (0.07-0.53), 0.06 (0.01-0.24)
175 and 0.04 (0.01-0.15) for previous infection, breakthrough infection and reinfection, respectively;
176 $p<0.001$, Supplementary table 5). Males had higher odds to lose this ability (adjusted OR (95% CI):
177 2.64 (1.12-6.56); $p=0.030$, Supplementary table 5). Compared to the participants aged <40 years, those
178 aged 40-64 years and ≥ 65 years had higher odds to lose Omicron neutralization capacity (adjusted OR
179 (95% CI): 5.74 (1.87-22.19) and 7.89 (2.02-36.13), respectively; $p=0.008$, Supplementary table 5).
180 Importantly, ethnic community was not associated with the loss of Omicron neutralization capacity
181 between D3.1 and D3.6 (Supplementary table 5).

182 ADCC activation remained stable between D3.1 and D3.6 (median (95% CI) difference (+0.20 AU (-
183 0.41; 0.61)). The multivariate linear regression model showed that the capacity to mediate ADCC in
184 female participants who were never infected remained stable in time (mean (95% CI) progression -0.16
185 (-0.53; 0.21)) (Supplementary table 6). In participants with breakthrough infection between D3.1 and
186 D3.6, the capacity to mediate ADCC significantly increased between D3.1 and D3.6 (mean (95% CI)
187 progression of +0.51 AU (0.13; 0.88), $p=0.0087$). In male participants, the capacity to mediate ADCC
188 significantly decreased between D3.1 and D3.6 (mean (95% CI) progression of -0.47 AU (-0.85; -0.08),
189 $p<0.018$). Importantly, the ethnic community was not associated with an evolution in the capacity to
190 mediate ADCC ($p=0.80$ in univariate linear regression).

191 *Humoral response to SARS-CoV-2 at 6 months post-third dose is similar across ethnic communities*

192 Among the 488 participants sampled at D3.6, 119 self-declared as Melanesians, 166 as Europeans, 68
193 as Polynesians and 135 belonged to other communities (Supplementary table 7). Europeans were older,

194 had lower BMIs, exhibited signs of previous infection less frequently and were less able to neutralize
195 Omicron. Past infection was significantly more frequent in Melanesians and “other communities”
196 ($p<0.001$, Khi^2 test). Previous infection was significantly associated with higher anti-S IgG levels (crude
197 effect +1.16, 95% CI (0.91; 1.41), $p<0.001$, Supplementary table 8). Melanesians and other communities
198 showed higher anti-S IgG levels in univariate analysis. In multivariate analysis, only the infection status
199 remained significantly associated with higher anti-S IgG levels.

200 Of these participants, 362 (74.2%) showed ability to neutralize Omicron. In the multivariate model,
201 previous infection and higher anti-S IgG levels were independently associated with higher odds of
202 neutralization at D3.6 (adjusted OR (95% CI): 4.04 (2.54-6.50), $p<0.001$ and 51.64 (11.00-922.94),
203 $p<0.001$, respectively; Supplementary table 9). Conversely, males had lower odds to neutralize Omicron
204 (adjusted OR (95% CI): 0.61 (0.38-0.97), $p=0.024$). As compared to participants aged <45 years, those
205 aged 40-64 years and ≥ 65 years also had lower odds to neutralize Omicron (adjusted OR (95% CI): 0.48
206 (0.24-0.90) and 0.29 (0.14-0.57), $p=0.0024$). Capacity to neutralize Omicron at D3.6 was independent
207 of the ethnic community.

208 **Discussion**

209 This study found that Europeans, Melanesians, Polynesians and other communities had equivalent anti-S
210 IgG titers and capacity to neutralize Omicron and mediate ADCC following Pfizer BNT162b2
211 vaccination and SARS-CoV-2 infection. They showed a similar maintenance of their hybrid humoral
212 response 6 months after immunization. Melanesians’ and other communities’ higher anti-S IgG levels
213 at D3.6 were associated with more frequent infections, probably resulting from different lifestyles across
214 communities in NC, which may favor transmission ².

215 Population genetic studies have revealed that ancient admixture between humans and Denisovans left
216 traces in present-day Pacific Islanders’ genomes ¹⁵, introducing genetic variants almost exclusively
217 related to immune response regulation ¹⁶. How genetic traits from archaic humans contribute to
218 phenotypic differences between contemporary individuals, especially relating to their immune response,
219 is poorly known. We showed here that Pacific Islanders’ genetic uniqueness did not translate in

220 differential hybrid humoral response to SARS-CoV-2. Although some genetic variants have been
221 associated with antigen-specific IgG levels ¹⁷, neither their presence in Pacific populations nor their
222 impact on anti-SARS-CoV-2 IgG levels have been explored. Our results are consistent with robust
223 antibody response and neutralization after two doses of BNT162b2 vaccine in a cohort comprising 80
224 Pacific people ¹¹. Such efficient hybrid humoral response of Pacific Islanders highlights the importance
225 of pursuing vaccination efforts in this population at risk for severe COVID-19.

226 We found that hybrid immunity resulting from BNT162b2 vaccination and SARS-CoV-2 infection was
227 highly prevalent in our cohort. Due to COVID-19 epidemiology in NC (Supplementary figure 1),
228 infected participants sampled at D2.1 or later timepoints were likely infected by the Delta variant, or
229 either by the Delta or Omicron variants, respectively. In our study, hybrid immunity translated in a
230 robust anti-S IgG secretion with efficient Omicron neutralization capacity compared to non-infected
231 vaccinees, in Pacific Islanders as well. A third dose of BNT162b2 vaccine resulted in Omicron
232 neutralization in almost all participants, independently from a previous infection. Consistently, hybrid
233 immunity was shown to boost antibody levels and poly-functionality regardless of the sequence of
234 natural infection and vaccination ¹⁸, resulting in a significant and lasting protection against Omicron
235 infection ¹⁹. Recall of memory B cells generated after the original infection contributes to this increase
236 in variant-neutralizing antibodies after vaccination ²⁰. Enhancement of variant-neutralizing capacity in
237 infected vaccinees supports the relevance to vaccinate Pacific Islanders, who exhibit higher COVID-19
238 seroprevalences (*Huet et al., in prep*).

239 We observed that self-declared males had lower anti-S IgG titers at one month after immunization,
240 which did not translate in differential neutralization capacity. Sex did not affect antibody decline
241 between D3.1 and D3.6. However, the loss of Omicron neutralization capacity between D3.1 and D3.6
242 was more likely in males, resulting in lower odds of Omicron neutralization at D3.6. Furthermore, the
243 capacity to mediate ADCC was enhanced at one-month post-immunization but decreased more rapidly
244 in males. Consistently, males were shown to secrete lower antibody levels after two doses of BNT162b2
245 ²¹. However, anti-S IgG levels were shown to decline faster in males after infection ²². Higher antibody
246 titers in females were observed for several vaccines ^{23,24}, suggesting a differential effective vaccine dose

247 according to sex. Overall, while several studies demonstrated an impact of sex on the humoral response
248 ^{22,25}, the underlying mechanisms remain poorly characterized.

249 In addition, we found that age did not affect antibody decline between D3.1 and D3.6, probably due to
250 significantly lower anti-S IgG levels in the ≥ 40 years age groups at one-month after immunization.
251 Consistently, older individuals exhibit lower antibody levels after two doses of BNT162b2, with similar
252 decline across ages ²¹. Individuals aged ≥ 40 years had lower odds of Omicron neutralization at D3.6.
253 Age might therefore impact humoral response polyfunctionality. SARS-CoV-2 vaccination's outcome
254 correlates with signs of immunosenescence ²⁶, probably contributing to this loss of Omicron
255 neutralization in older individuals. This highlights the importance to offer booster doses to the elderly
256 to prevent the loss of Omicron neutralization capacity, in Pacific Islanders as well.

257 In this study, higher BMIs were associated with higher anti-S IgG levels at one-month post-
258 immunization, in turn associated with higher odds of Omicron neutralization. However, impact of BMI
259 on humoral immunity to natural infection and BNT162b2 vaccination is controversial ²⁷⁻²⁹. Nonetheless,
260 this result emphasizes the benefits of vaccinating obese individuals, who are overrepresented among
261 Pacific Islanders.

262 The current study suffers limitations: first, the high rate of SARS-CoV-2 infections prevented to assess
263 ethnicity's impact on the humoral response to vaccination alone. Nonetheless, infection status was taken
264 into consideration in multivariate models. As SARS-CoV-2 immunity worldwide is predominantly
265 hybrid, characterization of a population's immunity, independently of its infection status, is highly
266 relevant to adapt Public Health strategies. Second, the current study relied on self-declared ethnicity,
267 without genetic determination of ancestry. Although mixed marriages are common, participants had the
268 opportunity to identify as "Other communities" including metis. Self-declared ethnicity was thus an
269 appropriate surrogate to genetically-determined ancestry. Finally, the sample size was not reached,
270 hindering to ascertain response equivalence between communities. However, the lack of community
271 effect, despite different prevalence of obesity, strongly suggests that SARS-CoV-2 hybrid humoral
272 response does not differ between communities.

273 Overall, by investigating the hybrid immune response of Pacific Islanders to SARS-CoV-2, our study
274 sheds light on the health of a population neglected in human studies, opening the door to considering
275 Pacific Islanders' uniqueness in Health studies.

276 **Methods**

277 *Ethics*

278 The current study was conducted in compliance with the Declaration of Helsinki principles and recorded
279 on clinicaltrials.gov (ID: NCT05135585). Samples came from participants who gave their written
280 informed consent as part of this study. This study was approved by the "Comité de Protection des
281 Personnes Ile-de-France III" (n° ID-RCB 2021-A01949-32, CPP n° 4003-I, November 9th 2021,
282 Am8898-1-4003 January 17th, 2022, Am9503-2-4003 April, 4th 2022 and Am9508-3-4003 June 21st,
283 2022) and by the Consultative Ethics Committee of New Caledonia.

284 *Cohort and study design*

285 Enrolment took place in immunization centres in the South Province of NC, where adults (≥ 18 years)
286 who received the Pfizer BNT162b2 vaccine were approached. Initially, individuals who received their
287 second dose were approached. When the 3rd dose was rolled out, participants who received their 3rd dose
288 were approached. In a third phase, individuals having received a 3rd dose within the last 6 months were
289 also approached (Figure 1). Documented SARS-CoV-2 infection (serologic, PCR or antigenic testing)
290 was an exclusion criterion. Pregnant or breast-feeding women, immunosuppressed individuals,
291 individuals unable to answer the questionnaire and those under protective measures were excluded.
292 Sample size calculation for this equivalence study was based on a power of 85% to detect changes of
293 more than 5% in the fraction of participants developing anti-S IgG in response to Pfizer BNT162b2
294 vaccination, with an alpha risk of 5%, resulting in the requirement to enroll 141 participants in each
295 community.

296 Clinico-epidemiological data were recorded at enrolment in RedCap (Vanderbilt University, USA). A
297 home visit by a qualified nurse was arranged one month (+/- 10 days) after the second or third dose and
298 either 3 months after the second dose or 6 months after the third dose. Upon these visits, a 4-mL venous

299 blood sample was collected. Not all participants enrolled in the study participated to the follow-up. Sera
300 were separated from blood samples by centrifugation and stored at -20°C until subsequent analyses.

301 *Cells and reagents*

302 HEK 293T-hACE2 cells were cultured at 37°C under 5% CO₂ in complete culture medium composed
303 of Dulbecco's modified Eagle's medium (DMEM, Gibco) complemented with 10% fetal calf serum
304 (Gibco), 1% penicillin/streptomycin (Gibco) and 2mM L-Glutamine (Gibco). Cells were detached and
305 resuspended using 0.05% Trypsin-EDTA (Gibco).

306 Recombinant SARS-CoV-2 Wuhan Spike or Nucleocapsid proteins were kindly provided by S. Petres
307 ³⁰. Secondary lama antibodies VHH anti-human IgG Fc coupled to NanoKAZ were kindly provided by
308 Thierry Rose. Z108 NanoKAZ substrate was kindly provided by Yves Janin.

309 *Pseudotyped viruses*

310 Pseudotyped lentiviral vectors enveloped with the Spike protein from Wuhan, Delta, Omicron BA.1 or
311 Omicron BA.4/5 SARS-CoV-2 variants were produced as previously described ²⁹. Briefly, HEK 293T
312 cells were co-transfected with a packaging plasmid Gag-Pol (NR-52517, BEI Resources), Helper
313 Plasmids Tat1b (NR-52518, BEI Resources) and Rev1b (NR-52519, BEI Resources), a transfer plasmid
314 carrying the gene encoding the Spike Glycoprotein of Wuhan-Hu-1 (GenBank: NC_045512, plasmid
315 NR-52514, BEI Resources), Delta, Omicron BA.1 or Omicron BA.4/5 SARS-CoV-2 variants and a
316 Lentiviral Backbone carrying a luciferase reporter gene Luc2 and a ZsGreen gene (pHAGE-CMV-Luc2-
317 IRES-ZsGreen-W, NR-52516, BEI Resources). At 48h post-transfection, supernatants were collected,
318 clarified by centrifugation and frozen at -80°C.

319 *LuLISA experiments*

320 Sera were decomplexed at 56°C for 35 min. White 384-well tissue-culture plates (Greiner Bio-one)
321 were coated with recombinant SARS-CoV-2 Wuhan Spike or Nucleocapsid proteins at 1 µg/mL in
322 Phosphate Buffer Saline (PBS, Gibco) through 4h incubation at room temperature. Plates were washed
323 with PBS containing 0.1% Tween (Tween®20, Sigma-Aldrich) using a plate washer Zoom microplate

324 Washer (Titertek Berthold). Sera were diluted 1/200 in PBS containing 1% skimmed milk and 0.1%
325 Tween using a Tecan Fluent 780 and incubated in duplicate for 2h in Spike- or Nucleoprotein-coated
326 plates. Plates were washed with PBS containing 0.1% Tween. Secondary VHH lama antibodies anti-
327 human IgG Fc coupled to NanoKAZ were diluted at 20 ng/mL in PBS containing 1% skimmed milk
328 and 0.1% Tween and added to the plates. After 1h30 incubation, Z108 NanoKAZ substrate was added
329 to the plates at 6 µg/mL. Bioluminescence was measured using Mithras² LB943 Multimode reader
330 luminometer (Berthold technologies). Presence of anti-Spike IgG above the 0.25 AU was indicative of
331 an immunization against SARS-CoV-2. Past COVID-19 infection was determined by the presence of
332 anti-Nucleocapsid antibodies above 0.3 AU.

333 *Pseudovirus neutralization assay*

334 Decomplemented sera (56°C for 35 min) were diluted 1/40 and coincubated with pseudotyped lentiviral
335 vectors at room temperature for 50 min in complete culture medium prepared using DMEM without
336 phenol red (Gibco). The mixture was then plated in white 96-well tissue-culture plates (Greiner Bio-
337 One). A suspension of 20,000 HEK 293T-hACE2 cells was added in each well. Single-cell suspensions
338 were prepared in Dulbecco's Phosphate Buffer Saline (DPBS) containing 0.1% EDTA (Promega) to
339 preserve hACE2 protein integrity. Serum-lentivirus mixes and addition of the cells were all performed
340 using a Tecan Fluent 780. After 72h, Bright-Glo Luciferase substrate (Promega) was added to the cells
341 (1:1). Bioluminescence was measured using Centro XS3 LB 960 or Mithras² LB943 Multimode reader
342 luminometers (Berthold technologies).

343 A set of negative sera was used to determine the threshold as the average luminescence level of these
344 negative sera minus 3 standard deviations.

345 The percentage of neutralization was expressed as $(1 - (\text{measured value}/\text{threshold})) \times 100$. The ability
346 to neutralize Omicron variant was defined in pseudovirus neutralization assays as $\geq 90\%$ neutralization
347 of Omicron BA.1 and/or Omicron BA.4/5 pseudoviruses by a 1/40 dilution of the serum (ie
348 neutralization titer >40).

349 *Antibody-Dependent Cellular Cytotoxicity (ADCC)*

350 CD16 activation was quantified as a surrogate assay to measure sera's capacity to mediate ADCC.
351 ADCC was quantified using the ADCC Reporter Bioassay (Promega) and 293T cells stably expressing
352 the Wuhan spike. Briefly, spike-expressing cells (3×10^4 per well) were co-cultured with Jurkat-CD16-
353 NFAT-rLuc cells (3×10^4 per well) in presence or absence of sera diluted 1/30. Luciferase was measured
354 after 18h of incubation using an EnSpire plate reader (PerkinElmer). ADCC was measured as the fold
355 induction of Luciferase activity compared to the "no serum" condition. For each serum, the control
356 condition (cells transfected with an empty plasmid) was subtracted to account for inter-individual
357 variations of the background. We previously reported correlations between the ADCC Reporter
358 Bioassay titers and an ADCC assay based on primary NK cells and cells infected with an authentic virus
359 ¹³. ADCC analyses were conducted on all samples collected at one-month post-immunization but two
360 and on all corresponding follow-up samples collected 6 months after the 3rd dose.

361 *Statistical analyses*

362 Quantitative variables were characterized by the median, inter-quartile range (IQR) and range. Age was
363 categorized into three groups: 18-39, 40-64 and ≥ 65 years. Participants with a Body Mass Index (BMI)
364 strictly below 18.5 kg/m^2 , comprised between 18.5 and 24.9 kg/m^2 , comprised between 25 and 29.9
365 kg/m^2 or over 30 kg/m^2 were considered as underweight, normal weight, overweighted or obese,
366 respectively.

367 Proportions were compared using Chi-2 test. Continuous variables were compared using Kruskal-Wallis
368 test. The effect of immunization dose, infection status, self-declared gender, age, BMI category,
369 presence of comorbidities and self-declared ethnicity on the levels of anti-Spike antibodies and CD16
370 activation was investigated using linear regression models. Their effect on Omicron neutralization
371 capacity was investigated using logistic regression models. In all analyses, factors associated with the
372 outcome with a p -value < 0.20 in univariate analyses were considered in the multivariate model. Then,
373 a backward stepwise procedure was used to identify factors that remained independently associated with
374 the outcome. A p -value < 0.05 was considered significant. All statistical analyses were performed using
375 R software (version R 4.2.1 GUI 1.79 High Sierra build (8095)).

376 **Notes**

377 *Author contributions*

378 CI, MDR and VAD conceived the study. CI and MDR led the applications for funding with input from
379 AC, GM, MJ and VAD. Consent and questionnaire tools were designed by CI and MDR. Inclusions
380 were implemented by CI, AC, AFG, GM, VAD and MDR. Samples were collected by home-visiting
381 nurses and handled by AB, ACG and AFG. CI, CS, AB, TB, VE, SM, OS and SW performed the
382 experimentations. CI, AC and TD implemented the statistical analyses under the supervision from YM.
383 CI wrote the scientific manuscript with input from YM, MDR and all authors. All authors have had the
384 opportunity to access the underlying data used in this study. All authors reviewed the manuscript and
385 approved the final version prior to submission.

386 *Financial support*

387 This study received financial support from the ANRS | Emerging infectious diseases, the Pasteur
388 Network COVID-19 funding, the Institut Pasteur in New Caledonia, the Specialized Hospital from New
389 Caledonia, the Provincial Office for Health and Social Action in the South Province in New Caledonia
390 (DPASS-Sud) and the Regional Hospital Federation in the South Pacific (FHF).

391 *Acknowledgements*

392 We would like to thank all the participants to the COVCAL study. This study has been labeled as a
393 National Research Priority by the National Orientation Committee for Therapeutic Trials and other
394 researches on COVID-19 (CAPNET). The investigators would like to acknowledge ANRS | Emerging
395 infectious diseases for its scientific support and funding, the French Ministry of Health and Prevention
396 and the French Ministry of Higher Education, Research and Innovation for their funding and support.
397 We warmly thank the Clinical Research Department of the Centre for Translational Research at Institut
398 Pasteur in Paris for their support in ethic procedures. The authors would also like to thank Priscillia
399 Piersanti, Aurore Martini, Sabine Crescentini, Dr Christophe Assié and Dr Johanna Read along with
400 home-visiting nurses and personnel from Medical Centers for their support in the investigation,
401 Stéphane Petres and the Plateforme Technologique de Production et Purification de Protéines

402 Recombinantes at Institut Pasteur for the production of the N and S proteins used in the LuLISA assays,
403 Faustine Amara, Margot Penru, Yannis Rahou and Lou-Léna Vrignaud for technical support and Dr
404 Etienne Simon-Lorière and Pr John Aaskov for insightful discussions.


405 *Declaration of interests*

406 All authors declare no competing interests.

407 *Data sharing*

408 Further information and requests for reagents and resources should be directed to and will be fulfilled
409 by the corresponding author, Catherine Inizan (cinizan@pasteur.nc).

410 **Figures and Figure Legends**




411

Figure 1

412 **Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagrams of the second- and**
413 **third-dose cohorts. A.** The second dose cohort is composed of 126 pre-included participants, among
414 which 68 were sampled one month after their second dose (purple square). **B.** The third-dose cohort is
415 composed of 554 pre-included participants, among which 237 were sampled one month after their third
416 dose (purple square), 214 were followed-up at one and six months after their third dose (bold frames)
417 and 488 were sampled at 6 months after their third dose (blue square).

418

Distribution of the 849 samples




419


Figure 2

420 **Figure 2. Description of the sample set.** The 849 samples are divided into anti-N IgG (IgN) negative
421 samples coming from vaccinated participants with no traces of previous infection (violet), and anti-N
422 IgG positive samples coming from infected participants (red), breakthrough infections between one and
423 three months post-second dose (brown), breakthrough infections between one and six months post-third
424 dose (green) or reinfected participants (blue).

A. Magnitude of the humoral response one month after immunization



B. Magnitude of the humoral response across communities one month after immunization



C. Neutralization capacity against SARS-CoV-2 variants




Figure 3

426 **Figure 3. Measure of anti-S IgG levels and neutralization capacity. A.** Concentrations in anti-S IgG
427 in samples collected one month after the second dose from previously infected participants (D2.1
428 infected, red), one month after the second dose from previously non-infected participants (D2.1 non
429 infected, green), one month after the third dose from previously infected participants (D3.1 infected,
430 blue) and one month after the third dose from previously non-infected participants (D3.1 non infected,
431 purple). **B.** Concentrations in anti-S IgG in samples collected from self-declared Melanesian (dark blue),
432 European (light blue), Polynesian (light green) participants or from participants self-declaring as
433 belonging to other communities (dark green) one month after immunization. **C.** Heatmap of the
434 neutralization capacity against SARS-CoV-2 variants Wuhan, Delta, Omicron BA.1 and Omicron
435 BA.4/5 one month after the second dose in previously non-infected participants (D2.1 non infected,
436 green), one month after the second dose in previously infected participants (D2.1 infected, red), one
437 month after the third dose in previously non-infected participants (D3.1 non infected, violet) and one
438 month after the third dose in previously infected participants (D3.1 infected, blue). Gradient between
439 dark blue and yellow denotes increasing neutralization capacity from 0% to 100% of 1/40 diluted sera.
440 Each line represents one participant.

441 **Tables**

442 **Table 1. Factors associated with anti-S IgG levels one month after immunization (linear**
 443 **regression)**

	N=305	Crude effect (95% CI)	p value	Adjusted effect (95% CI)	p value
Timepoint			<0.001		<0.001
Post 2nd dose	68	<i>Reference</i>		<i>Reference</i>	
Post 3rd dose	237	+1.24 (1.02; 1.46)		+1.27 (1.06; 1.49)	
Infected			0.004		<0.001
No	108	<i>Reference</i>		<i>Reference</i>	
Yes	197	+0.33 (0.11; 0.56)		+0.38 (0.19; 0.56)	
Gender^a			0.051		0.036
Male	138	-0.18 (-0.36; 0.001)		-0.19 (-0.37; -0.01)	
Female	167	<i>Reference</i>		<i>Reference</i>	
Age (years)^a			0.046		
18-39	130	<i>Reference</i>			
40-64	133	-0.14 (-0.34; 0.06)			
≥65	42	-0.35 (-0.63; -0.06)			
Comorbidities^a			0.51		
No	173	<i>Reference</i>			
Yes	132	-0.06 (-0.25; 0.12)			
BMI^a			0.017		0.008
Underweight	9	-0.26 (-0.80; 0.29)		-0.48 (-1.05; 0.10)	
Normal	93	<i>Reference</i>		<i>Reference</i>	
Overweight	90	-0.04 (-0.27; 0.19)		+0.05 (-0.28; 0.18)	
Obese	113	+0.26 (0.04; 0.48)		+0.24 (0.03; 0.46)	
Community^a			0.17		
European	79	<i>Reference</i>			
Melanesian	55	+0.02 (-0.26; 0.30)			
Polynesian	55	+0.24 (-0.04; 0.52)			
Other	116	+0.20 (-0.03; 0.44)			

444 ^aThe univariate analysis is adjusted for timepoint and infection status.

445 CI: confidence interval; BMI: body mass index.

446 BMI classes: Underweight = BMI < 18.5 kg/m², Normal weight = BMI ∈ [18.5, 25[kg/m², Overweight

447 = BMI ∈ [25, 30[kg/m², Obese = BMI ≥ 30 kg/m²

448 Statistically significant associations (p < 0.05) with anti-S IgG levels are shown in bold.

449 **Table 2. Factors associated with the ability to neutralize Omicron BA.1 and/or BA.4-5 one**
 450 **month after the second and third dose (logistic regression)**

<i>One month after the second dose</i>				
	N=68	Neutralisation, n (%)	Crude OR (95% CI)	p value
Infected^a	No	21	0 (0)	16.83 (2.04-2.19)
	Yes	47	13 (27.7)	
Level of anti-S IgG	<5.737 AU	56	3 (5.4)	88.33 (15.79-805.92)
	≥ 5.737 AU	12	10 (83.3)	
Gender	Male	31	5 (16.1)	0.70 (0.19-2.36)
	Female	37	8 (21.6)	
Age (years)^a	18-39	42	9 (21.4)	0.96 (0.25-3.30)
	40-64	20	4 (20.0)	
	≥65	6	0 (0)	
Comorbidities	No	38	8 (21.1)	0.75 (0.20-2.54)
	Yes	30	5 (16.7)	
BMI	Normal weight	20	2 (10)	4.24 (0.90-30.81)
	Overweight	23	3 (13.0)	
	Obese	25	8 (32)	
Community	European	16	3 (18.8)	1.73 (0.38-9.54)
	Melanesian	22	3 (13.6)	
	Polynesian	9	1 (11.1)	
	Other	21	6 (28.6)	
<i>One month after the third dose</i>				
	N=237	Neutralisation, n (%)	Crude OR (95% CI)	p value
Infected	No	87	84 (96.6)	2.64 (0.43-20.36)
	Yes	150	148 (98.7)	
Level of anti-S IgG	<5.737 AU	62	58 (93.5)	12.00 (1.73-237.30)
	≥ 5.737 AU	175	174 (99.4)	
Gender	Male	130	128 (98.5)	0.54 (0.07-3.33)
	Female	107	104 (97.2)	
Age (years)^a	18-39	88	88 (100)	0.13 (0.00-2.57)
	40-64	113	109 (96.5)	
	≥65	36	35 (97.2)	
Comorbidities	No	135	133 (98.5)	0.50 (0.06-3.05)
	Yes	102	99 (97.1)	
BMI	Underweight	8	7 (87.5)	2.42 (0.23-52.63)
	Normal weight	74	72 (97.3)	
	Overweight	67	66 (98.5)	
	Obese	88	87 (98.9)	
Community^a				0.60

European	63	61 (96.8)	1	
Melanesian	33	33 (100)	2.72 (0.21-379.95)	
Polynesian	46	44 (95.7)	0.72 (0.11-4.85)	
Other	95	94 (98.9)	2.56 (0.33-28.48)	

451 *CI: confidence interval; BMI: body mass index, OR: Odds Ratio.*

452 *^aLogistic regression with Firth's correction.*

453 *BMI classes: Underweight = BMI < 18.5 kg/m², Normal weight = BMI ∈ [18.5, 25[kg/m², Overweight*

454 *= BMI ∈ [25, 30[kg/m², Obese = BMI ≥ 30 kg/m²*

455 *Statistically significant associations (p < 0.05) with the ability to neutralize Omicron BA.1 and/or*

456 *BA.4-5 are shown in bold.*

457

458 **Table 3. Factors associated with the level of ADCC (CD16 activation) one month after**
 459 **immunization (Linear regression)**

	n=303	Crude effect (95% CI)	p value	Adjusted effect (95% CI)	p value
Timepoint			0.10		
Post 2nd dose	66	<i>Reference</i>			
Post 3rd dose	237	+0.33 (-0.06; 0.73)			
Infected			0.30		
No	108	<i>Reference</i>			
Yes	195	+0.18 (-0.16; 0.53)			
Level of anti-S IgG			<0.001		<0.001
<5.737 AU	117	<i>Reference</i>		<i>Reference</i>	
≥ 5.737 AU	186	+0.58 (0.25; 0.92)		+0.61 (0.29; 0.94)	
Gender			0.010		0.005
Male	136	+0.43 (0.10; 0.76)		+0.47 (0.14; 0.79)	
Female	167	<i>Reference</i>		<i>Reference</i>	
Age (years)			0.48		
18-39	129	<i>Reference</i>			
40-64	132	0.13 (-0.22; 0.48)			
≥65	42	-0.17 (-0.68; 0.34)			
Comorbidities			0.60		
No	172	<i>Reference</i>			
Yes	131	-0.10 (-0.43; 0.23)			
BMI			0.25		
Underweight	8	-1.06 (-2.11; -0.01)			
Normal	94	<i>Reference</i>			
Overweight	89	-0.07 (-0.49; 0.35)			
Obese	113	-0.14 (-0.54; 0.26)			
Community			0.05		
European	78	<i>Reference</i>			
Melanesian	54	-0.71 (-1.21; -0.20)			
Polynesian	55	-0.36 (-0.86; 0.14)			
Other	116	-0.35 (-0.76; 0.07)			

460 *CI: confidence interval; BMI: body mass index.*

461 *BMI classes: Underweight = BMI < 18.5 kg/m², Normal weight = BMI ∈ [18.5, 25[kg/m², Overweight*

462 *= BMI ∈ [25, 30[kg/m², Obese = BMI ≥ 30 kg/m²*

463 *Statistically significant associations (p < 0.05) with ADCC levels are shown in bold.*

464

465

466

467 **Supplementary information titles and legends**

468 **Supplementary Figure 1. Distribution of samples according to COVID-19 epidemiology in New**
469 **Caledonia.** Absolute number of cases are shown in black on the left y axis, with Delta, Omicron BA.1
470 and Omicron BA.4/5 epidemic peaks. Absolute number of samples collected one month after the second
471 dose (orange), three months after the second dose (green), one month after the third dose (blue) or 6
472 months after the third dose (violet) are shown on the right y axis. Inclusion periods are shown below the
473 graph.

474 **Supplementary Figure 2. ROC curve for the anti-S IgG threshold best discriminating samples**
475 **exhibiting Omicron neutralization capacity.**

476

477 **Supplementary Table 1.** Participants' description at baseline (1 month after the 2nd or 3rd dose)

478 **Supplementary Table 2.** Comparison of immune characteristics after the 2nd or 3rd dose

479 **Supplementary Table 3.** Description of the participants followed up at month 1 and month 6 post-3rd
480 dose of vaccination (N=214)

481 **Supplementary Table 4.** Factors associated with the progression of anti-S IgG levels between one
482 and six months after immunization (linear regression)

483 **Supplementary Table 5.** Factors associated with the loss of the ability to neutralize Omicron BA.1
484 and/or BA.4-5 between one and six months after immunization (logistic regression)

485 **Supplementary Table 6.** Factors associated with the variation in the level of ADCC (CD16
486 activation) between one and six months after immunization (linear regression)

487 **Supplementary Table 7.** Description of participants sampled at 6 months after the 3rd dose of
488 immunization

489 **Supplementary Table 8.** Factors associated with the levels of anti-S IgG six months after the 3rd dose
490 (linear regression)

491 **Supplementary Table 9.** Factors associated with the ability to neutralize Omicron BA.1 and/or BA.4-
492 5 six months after the 3rd dose (logistic regression)

493 References

- 494 1. Tarantola, A., Horwood, P.F., Goarant, C., Bertrand, S., Merilles, O.E.A., Pedron, T., Klement-
495 Frutos, E., Sansonetti, P., Quintana-Murci, L. & Richard, V. Counting Oceanians of Non-
496 European, Non-Asian Descent (ONENA) in the South Pacific to Make Them Count in Global
497 Health. *Trop Med Infect Dis* **4**(2019).
- 498 2. Horwood, P.F., Tarantola, A., Goarant, C., Matsui, M., Klement, E., Umezaki, M., Navarro, S. &
499 Greenhill, A.R. Health Challenges of the Pacific Region: Insights From History, Geography,
500 Social Determinants, Genetics, and the Microbiome. *Frontiers in Immunology* **10**(2019).
- 501 3. Burrage, R.L., Mills, K.J., Coyaso, H.C., Gronowski, C.K. & Godinet, M.T. Community Resilience
502 and Cultural Responses in Crisis: Lessons Learned from Pacific Islander Responses to the
503 COVID-19 Pandemic in the USA. *J Racial Ethn Health Disparities* **11**, 560-573 (2024).
- 504 4. Thomas, S.J., Moreira, E.D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez
505 Marc, G., Polack, F.P., Zerbini, C., *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19
506 Vaccine through 6 Months. *New England Journal of Medicine* **385**, 1761-1773 (2021).
- 507 5. ISEE-NC. Institut de la statistique et des études économiques Nouvelle-Calédonie,
508 Recensement. (2019).
- 509 6. DASS-NC. Direction des Affaires Sanitaires et Sociales de Nouvelle-Calédonie, Tableau de bord
510 COVID-19. (2023).
- 511 7. Ochida, N., Dupont-Rouzeyrol, M., Moury, P.H., Demaneuf, T., Gourinat, A.C., Mabon, S.,
512 Jouan, M., Cauchemez, S. & Mangeas, M. Evaluating the strategies to control SARS-CoV-2 Delta
513 variant spread in New Caledonia, a zero-COVID country until September 2021. *IJID Reg* **8**, 64-
514 70 (2023).
- 515 8. Secretariat of the Pacific Community, S. COVID-19 vaccination - Dataset - Pacific Data Hub.
516 (2023).
- 517 9. Khalil, L., Leary, M., Roupheal, N., Ofotokun, I., Rebolledo, P.A. & Wiley, Z. Racial and Ethnic
518 Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. *Vaccines (Basel)*
519 **10**(2022).
- 520 10. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez
521 Marc, G., Moreira, E.D., Zerbini, C., *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19
522 Vaccine. *New England Journal of Medicine* **383**, 2603-2615 (2020).
- 523 11. Priddy, F.H., Williams, M., Carson, S., Lavender, B., Mathieson, J., Frampton, C., Moreland, N.J.,
524 McGregor, R., Williams, G., Brewerton, M., *et al.* Immunogenicity of BNT162b2 COVID-19
525 vaccine in New Zealand adults. *Vaccine* **40**, 5050-5059 (2022).
- 526 12. Zhang, W., Kedzierski, L., Chua, B.Y., Mayo, M., Lonzi, C., Rigas, V., Middleton, B.F., McQuilten,
527 H.A., Rowntree, L.C., Allen, L.F., *et al.* Robust and prototypical immune responses toward
528 COVID-19 vaccine in First Nations peoples are impacted by comorbidities. *Nature Immunology*
529 **24**, 966-978 (2023).
- 530 13. Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann,
531 A., Planchais, C., Buchrieser, J., *et al.* Asymptomatic and symptomatic SARS-CoV-2 infections
532 elicit polyfunctional antibodies. *Cell Rep Med* **2**, 100275 (2021).
- 533 14. Yu, Y., Wang, M., Zhang, X., Li, S., Lu, Q., Zeng, H., Hou, H., Li, H., Zhang, M., Jiang, F., *et al.*
534 Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. *Signal*
535 *Transduction and Targeted Therapy* **6**, 346 (2021).
- 536 15. Reich, D., Green, R.E., Kircher, M., Krause, J., Patterson, N., Durand, E.Y., Viola, B., Briggs, A.W.,
537 Stenzel, U., Johnson, P.L., *et al.* Genetic history of an archaic hominin group from Denisova
538 Cave in Siberia. *Nature* **468**, 1053-1060 (2010).
- 539 16. Choin, J., Mendoza-Revilla, J., Arauna, L.R., Cuadros-Espinoza, S., Cassar, O., Larena, M., Ko,
540 A.M., Harmant, C., Laurent, R., Verdu, P., *et al.* Genomic insights into population history and
541 biological adaptation in Oceania. *Nature* **592**, 583-589 (2021).

- 542 17. Scepanovic, P., Alanio, C., Hammer, C., Hodel, F., Bergstedt, J., Patin, E., Thorball, C.W.,
543 Chaturvedi, N., Charbit, B., Abel, L., *et al.* Human genetic variants and age are the strongest
544 predictors of humoral immune responses to common pathogens and vaccines. *Genome Med*
545 **10**, 59 (2018).
- 546 18. Bates, T.A., McBride, S.K., Leier, H.C., Guzman, G., Lyski, Z.L., Schoen, D., Winders, B., Lee, J.Y.,
547 Lee, D.X., Messer, W.B., *et al.* Vaccination before or after SARS-CoV-2 infection leads to robust
548 humoral response and antibodies that effectively neutralize variants. *Sci Immunol* **7**, eabn8014
549 (2022).
- 550 19. Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z.,
551 Issa, H., *et al.* Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity
552 against the omicron variant and severe disease: a systematic review and meta-regression.
553 *Lancet Infect Dis* **23**, 556-567 (2023).
- 554 20. Crotty, S. Hybrid immunity. *Science* **372**, 1392-1393 (2021).
- 555 21. Wei, J., Pouwels, K.B., Stoesser, N., Matthews, P.C., Diamond, I., Studley, R., Rourke, E., Cook,
556 D., Bell, J.I., Newton, J.N., *et al.* Antibody responses and correlates of protection in the general
557 population after two doses of the ChAdOx1 or BNT162b2 vaccines. *Nat Med* **28**, 1072-1082
558 (2022).
- 559 22. Grzelak, L., Velay, A., Madec, Y., Gallais, F., Staropoli, I., Schmidt-Mutter, C., Wendling, M.-J.,
560 Meyer, N., Planchais, C., Rey, D., *et al.* Sex Differences in the Evolution of Neutralizing
561 Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. *The Journal of Infectious*
562 *Diseases* **224**, 983-988 (2021).
- 563 23. Klein, S.L. & Flanagan, K.L. Sex differences in immune responses. *Nature Reviews Immunology*
564 **16**, 626-638 (2016).
- 565 24. Cook, I.F. Sexual dimorphism of humoral immunity with human vaccines. *Vaccine* **26**, 3551-
566 3555 (2008).
- 567 25. Bunders, M.J. & Altfeld, M. Implications of Sex Differences in Immunity for SARS-CoV-2
568 Pathogenesis and Design of Therapeutic Interventions. *Immunity* **53**, 487-495 (2020).
- 569 26. Palacios-Pedrero, M., Jansen, J.M., Blume, C., Stanislawski, N., Jonczyk, R., Molle, A.,
570 Hernandez, M.G., Kaiser, F.K., Jung, K., Osterhaus, A., *et al.* Signs of immunosenescence
571 correlate with poor outcome of mRNA COVID-19 vaccination in older adults. *Nat Aging* **2**, 896-
572 905 (2022).
- 573 27. Kara, Z., Akçin, R., Demir, A.N., Dinç, H., Taşkın, H.E., Kocazeybek, B. & Yumuk, V.D. Antibody
574 Response to SARS-CoV-2 Vaccines in People with Severe Obesity. *Obes Surg* **32**, 2987-2993
575 (2022).
- 576 28. Bates, J.T., Farmer, A.P., Bierdeman, M.A., Ederer, D.R., Carney, L.S., Montgomery, D.D.,
577 Lirette, S.T. & Marshall, G.D. IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2
578 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity. *Vaccines (Basel)*
579 **10**(2022).
- 580 29. Crawford, K.H.D., Eguia, R., Dingens, A.S., Loes, A.N., Malone, K.D., Wolf, C.R., Chu, H.Y.,
581 Tortorici, M.A., Veesler, D., Murphy, M., *et al.* Protocol and Reagents for Pseudotyping
582 Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**, 513
583 (2020).
- 584 30. Grzelak, L., Temmam, S., Planchais, C., Demeret, C., Tondeur, L., Huon, C., Guivel-Benhassine,
585 F., Staropoli, I., Chazal, M., Dufloo, J., *et al.* A comparison of four serological assays for
586 detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. *Sci*
587 *Transl Med* **12**(2020).

588





Figure 1

Figure 1

Distribution of the 849 samples






Figure 2

Figure 2

A. Magnitude of the humoral response one month after immunization



B. Magnitude of the humoral response across communities one month after immunization



C. Neutralization capacity against SARS-CoV-2 variants




Figure 3

Figure 3